An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
NCT ID: NCT03779113
Last Updated: 2025-09-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE1
Total Enrollment
87 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-09-26
Study Completion Date
2025-03-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
NCT03786926
Lymphoma
TERMINATED
PHASE1
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
NCT01703572
Relapsed or Refractory Lymphoid Malignancies
COMPLETED
PHASE1
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00452127
Non-Hodgkin's Lymphoma
TERMINATED
PHASE1/PHASE2
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05190068
B-Cell Non-Hodgkin's Lymphoma
COMPLETED
PHASE1
A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
NCT03128164
Lymphomas
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).
Dose Escalation Stage (Stage 1)
Dosing will begin at 100 mg once daily (QD). A cycle of study treatment will be defined as 28 days of continuous dosing. The modified 3+3 design will be applied for dose escalation and MTD determination to limit the number of patients exposed to potentially ineffective or unsafe doses. The study will enroll 1 patient and the patient will be treated for a 28-day cycle in the initial dose cohort. If there is no Dose Limiting Toxicity (DLT) and no more than 2 treatment-emergent adverse events (TEAEs) of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 in the first treatment cycle, the study will be escalated to the next dose cohort and continue with the standard 3+3 design. Otherwise, the trial will revert to a standard 3+3 design from the initial dose cohort. A minimum of 3 patients will be enrolled and observed for toxicity in each successive dose cohort after the initial dose cohort. If the 3 patients initially enrolled in a given dose cohort complete the DLT assessment window (Cycle 1, Days 1-28) without experiencing a DLT, 3 patients will be enrolled at the next higher dose level. If 2 or more of the initial 3 patients enrolled at any dose level experience a DLT during the DLT assessment window, the dose escalation will be halted. If 1 of the initial 3 patients enrolled at any dose level experiences a DLT during the DLT assessment window, additional patients will be enrolled at that dose level for a minimum of 6 evaluable patients for DLT. If a DLT is observed in 1 of the 6 valuable patients at this dose level, dose escalation will proceed to the next pre- defined dose level. If DLTs are observed in 2 or more of the 6 evaluable patients at a given dose level, the dose escalation will be halted. If the dose escalation is completed due to 2 or more DLTs at a dose level and that dose level is ≥50% higher than the previous dose level, then an intermediate dose level may be evaluated for toxicity in the same manner as described above. If the dose level is \<50% higher than the previous dose level, in which only 3 DLT evaluable patients were enrolled, 3 additional patients will be enrolled at that dose level to comprise 6 DLT evaluable patients.
The proposed dose escalation scheme comprises Cohorts 1 to 5 with dosing levels of 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD and 800 mg QD, respectively. The need for dose escalation beyond 800 mg QD, the specific dose to be tested and the potential for twice-daily (BID) dosing will be evaluated jointly by investigators and the sponsor based on the cumulative clinical safety, pharmacokinetic, and preliminary efficacy data. Safety monitoring and evaluation of dose escalation will be carried out by the Safety Review Committee, which will be comprised of the sponsor's study team members (including medical monitor, safety monitor and and Pharmacokinetic scientist) and the site principal investigators. The adverse event profile and serum concentration of HMPL-523 data will be evaluated to determine whether it is safe to continue the assigned HMPL-523 dose for dose escalation or whether the dose should be de-escalated to the lower dose level.
Dose Expansion Stage (Stage 2)
The adverse event profile, serum concentration, and preliminary anti-tumor activity of HMPL-523 at the maximum tolerated dose(MTD)/recommended phase 2 dose(RP2D) will be further evaluated in approximately 50 patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphomas. The tumor types of the dose expansion stage are restricted to:
* 10 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
* 20 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post-BTK exposure
* 10 patients with mantle cell lymphoma
* 20 patients with follicular lymphoma (Grade 1-3a)
* 10 patients with marginal zone lymphoma
* 10 patients with waldenström's macroglobulinemia/lymphoplasmacytic lymphoma
* 10 patients with peripheral T- cell lymphoma
* 10 patients with cutaneous B-cell lymphoma
* 10 patients with hodgkin lymphoma
Patients will receive HMPL-523 at the MTD/RP2D for continuous 28-day treatment cycles until disease progression, death, intolerable toxicity, at investigator's discretion that the patient can no longer benefit from the study treatment, patient withdrawal from the study, or the end of study, whichever comes first.
Dose Escalation Stage (Stage 1)
Dosing will begin at 100 mg once daily (QD). A cycle of study treatment will be defined as 28 days of continuous dosing. The modified 3+3 design will be applied for dose escalation and MTD determination to limit the number of patients exposed to potentially ineffective or unsafe doses. The study will enroll 1 patient and the patient will be treated for a 28-day cycle in the initial dose cohort. If there is no Dose Limiting Toxicity (DLT) and no more than 2 treatment-emergent adverse events (TEAEs) of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 in the first treatment cycle, the study will be escalated to the next dose cohort and continue with the standard 3+3 design. Otherwise, the trial will revert to a standard 3+3 design from the initial dose cohort. A minimum of 3 patients will be enrolled and observed for toxicity in each successive dose cohort after the initial dose cohort. If the 3 patients initially enrolled in a given dose cohort complete the DLT assessment window (Cycle 1, Days 1-28) without experiencing a DLT, 3 patients will be enrolled at the next higher dose level. If 2 or more of the initial 3 patients enrolled at any dose level experience a DLT during the DLT assessment window, the dose escalation will be halted. If 1 of the initial 3 patients enrolled at any dose level experiences a DLT during the DLT assessment window, additional patients will be enrolled at that dose level for a minimum of 6 evaluable patients for DLT. If a DLT is observed in 1 of the 6 valuable patients at this dose level, dose escalation will proceed to the next pre- defined dose level. If DLTs are observed in 2 or more of the 6 evaluable patients at a given dose level, the dose escalation will be halted. If the dose escalation is completed due to 2 or more DLTs at a dose level and that dose level is ≥50% higher than the previous dose level, then an intermediate dose level may be evaluated for toxicity in the same manner as described above. If the dose level is \<50% higher than the previous dose level, in which only 3 DLT evaluable patients were enrolled, 3 additional patients will be enrolled at that dose level to comprise 6 DLT evaluable patients.
The proposed dose escalation scheme comprises Cohorts 1 to 5 with dosing levels of 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD and 800 mg QD, respectively. The need for dose escalation beyond 800 mg QD, the specific dose to be tested and the potential for twice-daily (BID) dosing will be evaluated jointly by investigators and the sponsor based on the cumulative clinical safety, pharmacokinetic, and preliminary efficacy data. Safety monitoring and evaluation of dose escalation will be carried out by the Safety Review Committee, which will be comprised of the sponsor's study team members (including medical monitor, safety monitor and and Pharmacokinetic scientist) and the site principal investigators. The adverse event profile and serum concentration of HMPL-523 data will be evaluated to determine whether it is safe to continue the assigned HMPL-523 dose for dose escalation or whether the dose should be de-escalated to the lower dose level.
Dose Expansion Stage (Stage 2)
The adverse event profile, serum concentration, and preliminary anti-tumor activity of HMPL-523 at the maximum tolerated dose(MTD)/recommended phase 2 dose(RP2D) will be further evaluated in approximately 50 patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphomas. The tumor types of the dose expansion stage are restricted to:
* 10 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
* 20 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post-BTK exposure
* 10 patients with mantle cell lymphoma
* 20 patients with follicular lymphoma (Grade 1-3a)
* 10 patients with marginal zone lymphoma
* 10 patients with waldenström's macroglobulinemia/lymphoplasmacytic lymphoma
* 10 patients with peripheral T- cell lymphoma
* 10 patients with cutaneous B-cell lymphoma
* 10 patients with hodgkin lymphoma
Patients will receive HMPL-523 at the MTD/RP2D for continuous 28-day treatment cycles until disease progression, death, intolerable toxicity, at investigator's discretion that the patient can no longer benefit from the study treatment, patient withdrawal from the study, or the end of study, whichever comes first.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Non Hodgkin Lymphoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
All patients to received study drug (HMPL-523)
Group Type
EXPERIMENTAL
HMPL-523
Intervention Type
DRUG
Oral HMPL-523
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HMPL-523
Oral HMPL-523
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patients must meet the following criteria to be eligible for study entry:
1. Signed informed consent form (ICF).
2. Age ≥18 years.
3. ECOG performance status of 0 or 1.
4. Histologically confirmed lymphoma, including Hodgkin's lymphoma and non-Hodgkin's lymphoma. In the dose expansion stage, the tumor types may be restricted to any or all of the following tumor types. There may be approximately 10 patients in each cohort depending on response signals suggesting efficacy, except for 2 identified cohorts with approximately 20 patients per cohort: relapsed or refractory CLL/SLL, CLL/SLL post-BTK exposure (n=20), MCL, FL (Grade 1-3a) (n=20), MZL, WM/LPL, PTCL,CBCL, and/or HL
5. Patients with relapsed or refractory lymphoma who have exhausted all approved therapy options.
6. In the dose expansion stage, patients must have measurable disease for an objective response assessment, except for patients with CLL and WM/LPL
7. Availability of tumor sample for patients in dose expansion cohorts: This may be an archival tissue sample obtained after most recent therapy or a fresh biopsy; if tumor sample is not available, the Sponsor may waive the requirement after discussion
8. Expected survival of more than 24 weeks as determined by the investigator.
9. Male patients must agree to use a condom and female patients of childbearing potential must agree to use highly effective contraceptive measures for 30 days after the last dose of study drug. These include as combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, and transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, and implantable), intrauterine contraceptive device, intrauterine hormone release system, bilateral tubal occlusion, or a vasectomized partner, provided that male partner is the sole sexual partner of the female patient. Postmenopausal females (women who have not had menses for at least 1 year without an alternative medical cause) are exempt from this criterion.
1. Signed informed consent form (ICF).
2. Age ≥18 years.
3. ECOG performance status of 0 or 1.
4. Histologically confirmed lymphoma, including Hodgkin's lymphoma and non-Hodgkin's lymphoma. In the dose expansion stage, the tumor types may be restricted to any or all of the following tumor types. There may be approximately 10 patients in each cohort depending on response signals suggesting efficacy, except for 2 identified cohorts with approximately 20 patients per cohort: relapsed or refractory CLL/SLL, CLL/SLL post-BTK exposure (n=20), MCL, FL (Grade 1-3a) (n=20), MZL, WM/LPL, PTCL,CBCL, and/or HL
5. Patients with relapsed or refractory lymphoma who have exhausted all approved therapy options.
6. In the dose expansion stage, patients must have measurable disease for an objective response assessment, except for patients with CLL and WM/LPL
7. Availability of tumor sample for patients in dose expansion cohorts: This may be an archival tissue sample obtained after most recent therapy or a fresh biopsy; if tumor sample is not available, the Sponsor may waive the requirement after discussion
8. Expected survival of more than 24 weeks as determined by the investigator.
9. Male patients must agree to use a condom and female patients of childbearing potential must agree to use highly effective contraceptive measures for 30 days after the last dose of study drug. These include as combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, and transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, and implantable), intrauterine contraceptive device, intrauterine hormone release system, bilateral tubal occlusion, or a vasectomized partner, provided that male partner is the sole sexual partner of the female patient. Postmenopausal females (women who have not had menses for at least 1 year without an alternative medical cause) are exempt from this criterion.
Exclusion Criteria
1. Patients with primary central nervous system (CNS) lymphoma.
2. Any of the following laboratory abnormalities: Absolute neutrophil count\<1.0×10\^9/L, Hemoglobin \<80 g/L, Platelets \<50×10\^9/L
3. Inadequate organ function, defined by the following: Total bilirubin \>1.5 times the upper limit of normal (× ULN), aspartate aminotransferase and/or alanine aminotransferase \>2.5 × ULN, Estimated Creatinine Clearance (CrCl) per Cockcroft-Gault \[Dose Escalation portion of trial (Stage 1) CrCl \< 40 mL/min, Dose Expansion portion of trial (Stage 2) CrCl \< 30 mL/min\], Serum amylase or lipase \>ULN, International normalized ratio \>1.5 × ULN, or activated partial thromboplastin time \>1.5 × ULN
4. Patients with clinically detectable second primary malignant tumors at enrollment or other malignant tumors within the last 2 years (with the exception of radically treated basal cell or squamous cell carcinoma of the skin, in situ cervix, or in situ breast cancer).
5. Any anticancer therapy, including chemotherapy, hormonal therapy, biologic therapy, vaccine, or radiotherapy within 3 weeks prior to the initiation of study treatment.
6. Herbal therapy within 1 week prior to the initiation of study treatment.
7. Prior use of any anti-cancer vaccine
8. Prior treatment with any spleen tyrosine kinase (SYK) inhibitors (eg, fostamatinib)
9. Prior administration of radioimmunotherapy within 3 months before initiation of study treatment.
10. Use of strong cytochrome P450 isoform 3A inhibitors and inducers and drugs metabolized by cytochrome P450 isoform 3A, cytochrome P450 isoform 2B6, and cytochrome P450 isoform 1A2, and are identified as narrow therapeutic drugs within 7 days or 3 half-lives, whichever is longer, prior to initiation of study treatment
11. Adverse events from prior anticancer therapy that have not resolved to Grade ≤1, except for alopecia.
12. Prior autologous stem cell transplant within 6 months prior to the initiation of study treatment.
13. Prior allogeneic stem cell transplant within 6 months prior to the initiation of study treatment or with any evidence of active graft versus host disease or requirement for immunosuppressants within 28 days prior to the initiation of study treatment.
14. Clinically significant active infection (eg, pneumonia).
15. Major surgical procedure within 4 weeks prior to the initiation of study treatment.
16. Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus.
17. Pregnant (positive serum beta human chorionic gonadotropin test) or lactating women.
18. New York Heart Association Class II or greater congestive heart failure.
19. Congenital long QT syndrome or correct QT interval using Fridericia's formula (QTcF) \>480 msec
20. Current use of medication known to cause QT prolongation or Torsades de Pointes
21. History of myocardial infarction or unstable angina within 6 months prior to the initiation of study treatment.
22. History of stroke or transient ischemic attack within 6 months prior to the initiation of study treatment.
23. Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease.
24. Treatment in a clinical study within 30 days prior to the initiation of study treatment.
25. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, or renders the patient at high risk from treatment complications.
2. Any of the following laboratory abnormalities: Absolute neutrophil count\<1.0×10\^9/L, Hemoglobin \<80 g/L, Platelets \<50×10\^9/L
3. Inadequate organ function, defined by the following: Total bilirubin \>1.5 times the upper limit of normal (× ULN), aspartate aminotransferase and/or alanine aminotransferase \>2.5 × ULN, Estimated Creatinine Clearance (CrCl) per Cockcroft-Gault \[Dose Escalation portion of trial (Stage 1) CrCl \< 40 mL/min, Dose Expansion portion of trial (Stage 2) CrCl \< 30 mL/min\], Serum amylase or lipase \>ULN, International normalized ratio \>1.5 × ULN, or activated partial thromboplastin time \>1.5 × ULN
4. Patients with clinically detectable second primary malignant tumors at enrollment or other malignant tumors within the last 2 years (with the exception of radically treated basal cell or squamous cell carcinoma of the skin, in situ cervix, or in situ breast cancer).
5. Any anticancer therapy, including chemotherapy, hormonal therapy, biologic therapy, vaccine, or radiotherapy within 3 weeks prior to the initiation of study treatment.
6. Herbal therapy within 1 week prior to the initiation of study treatment.
7. Prior use of any anti-cancer vaccine
8. Prior treatment with any spleen tyrosine kinase (SYK) inhibitors (eg, fostamatinib)
9. Prior administration of radioimmunotherapy within 3 months before initiation of study treatment.
10. Use of strong cytochrome P450 isoform 3A inhibitors and inducers and drugs metabolized by cytochrome P450 isoform 3A, cytochrome P450 isoform 2B6, and cytochrome P450 isoform 1A2, and are identified as narrow therapeutic drugs within 7 days or 3 half-lives, whichever is longer, prior to initiation of study treatment
11. Adverse events from prior anticancer therapy that have not resolved to Grade ≤1, except for alopecia.
12. Prior autologous stem cell transplant within 6 months prior to the initiation of study treatment.
13. Prior allogeneic stem cell transplant within 6 months prior to the initiation of study treatment or with any evidence of active graft versus host disease or requirement for immunosuppressants within 28 days prior to the initiation of study treatment.
14. Clinically significant active infection (eg, pneumonia).
15. Major surgical procedure within 4 weeks prior to the initiation of study treatment.
16. Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus.
17. Pregnant (positive serum beta human chorionic gonadotropin test) or lactating women.
18. New York Heart Association Class II or greater congestive heart failure.
19. Congenital long QT syndrome or correct QT interval using Fridericia's formula (QTcF) \>480 msec
20. Current use of medication known to cause QT prolongation or Torsades de Pointes
21. History of myocardial infarction or unstable angina within 6 months prior to the initiation of study treatment.
22. History of stroke or transient ischemic attack within 6 months prior to the initiation of study treatment.
23. Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease.
24. Treatment in a clinical study within 30 days prior to the initiation of study treatment.
25. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, or renders the patient at high risk from treatment complications.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hutchmed
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vijay Jayaprakash, MD
Role: STUDY_DIRECTOR
Hutchmed
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pacific Cancer Medical Center, Inc.
Anaheim, California, United States
Site Status
Innovative Clinical Research Institute
Downey, California, United States
Site Status
Ventura County Hematology-Oncology Specialists
Oxnard, California, United States
Site Status
Summit Medical Group
Florham Park, New Jersey, United States
Site Status
Clinical Research Alliance
New Hyde Park, New York, United States
Site Status
Leo Jenkins Cancer Center/ECU School of Medicine
Greenville, North Carolina, United States
Site Status
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Site Status
Renovatio Clinical
The Woodlands, Texas, United States
Site Status
Aarhus University Hospital
Aarhus, , Denmark
Site Status
Helsingin yliopistollinen keskussairaala
Helsinki, , Finland
Site Status
Tampereen yliopistollinen sairaala
Tampere, , Finland
Site Status
CHU Clermont Ferrand - Hôpital d'Estaing
Clermont-Ferrand, , France
Site Status
Hôpital Henri Mondor
Créteil, , France
Site Status
Groupe Hospitalier Pitie-Salpetriere
Paris, , France
Site Status
CHU Poitiers - Hôpital la Milétrie
Poitiers, , France
Site Status
Ospedale San Raffaele
Milan, Milano, Italy
Site Status
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
Bergamo, , Italy
Site Status
Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
Monza, , Italy
Site Status
KO-MED Centra Kliniczne
Biała Podlaska, , Poland
Site Status
Uniwersyteckie Centrum Kliniczne
Gdansk, , Poland
Site Status
Nasz Lekarz Przychodnie Medyczne
Torun, , Poland
Site Status
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego
Wroclaw, , Poland
Site Status
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Site Status
ICO Badalona - Hospital Universitari Germans Trias i Pujol
Barcelona, , Spain
Site Status
Institut Català d'Oncologia
Barcelona, , Spain
Site Status
Hospital Universitario Ramon y Cajal
Madrid, , Spain
Site Status
Fundacion Jimenez Diaz
Madrid, , Spain
Site Status
Hospital Universitario Infanta Leonor
Madrid, , Spain
Site Status
Hospital Universitario Quironsalud Madrid
Madrid, , Spain
Site Status
MD Anderson Cancer Centre
Madrid, , Spain
Site Status
Hospital Universitario Virgen del Rocio
Seville, , Spain
Site Status
Hospital Universitario Virgen Macarena
Seville, , Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Denmark
Finland
France
Italy
Poland
Spain
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-523-00US1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
NCT04818372
UNKNOWN
PHASE1
Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL
NCT02106091
TERMINATED
PHASE1
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
NCT04746131
SUSPENDED
PHASE1
Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients
NCT00081783
UNKNOWN
PHASE2
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
NCT02175433
COMPLETED
PHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
NCT01703481
COMPLETED
PHASE1
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03369964
WITHDRAWN
PHASE1
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
NCT03921879
UNKNOWN
PHASE1
Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients
NCT03127020
COMPLETED
PHASE2
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
NCT04657224
COMPLETED
PHASE1
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
NCT04240704
TERMINATED
PHASE1
A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT06622226
ACTIVE_NOT_RECRUITING
PHASE1
A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
NCT01013818
TERMINATED
PHASE1
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
NCT05144347
TERMINATED
PHASE1
AMG 319 Lymphoid Malignancy FIH
NCT01300026
COMPLETED
PHASE1
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
NCT01351935
COMPLETED
PHASE1
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
NCT00101244
TERMINATED
PHASE1
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
NCT00704691
TERMINATED
EARLY_PHASE1
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
NCT02631577
COMPLETED
PHASE1/PHASE2
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
NCT05293912
TERMINATED
PHASE1
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
NCT02567656
COMPLETED
PHASE1
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT00601718
COMPLETED
PHASE1/PHASE2
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT00511082
COMPLETED
PHASE1
Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
NCT00105313
TERMINATED
PHASE1
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
NCT05891821
RECRUITING
PHASE2